Radiolabeled antibody therapy of B-cell lymphomas.

Abstract

Patients with relapsed B-cell lymphomas are currently incurable with conventional doses of chemotherapy or radiotherapy. In recent years, new treatment options have become available for these patients, including the use of chimeric mouse-human anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. The nonradioactive rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) antibody induces remissions in 60% of patients with relapsed follicular lymphomas, including 5% to 10% complete remissions. Anti-CD20 antibodies radiolabeled with iodine 131 and yttrium 90 given at nonmyeloablative doses yield remissions in 75% to 80% of cases, including 35% to 40% complete remissions. High-dose (131)I-anti-B1 antibody with stem cell transplantation generates objective responses in 85% to 90% of cases, including 75% to 80% complete remissions. Although more patients need to be evaluated with a longer follow-up period, radioimmunotherapy appears to be an effective and well-tolerated addition to the oncologists' armamentarium for relapsed lymphomas.

• Authors: O W Press
• Journal: Seminars in oncology (Semin Oncol) Vol. 26 Issue 5 Suppl 14 Pg. 58-65 (Oct 1999) ISSN: 0093-7754 [Print] United States
• PMID: 10561019 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Iodine Radioisotopes
• Yttrium Radioisotopes
• Rituximab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Clinical Trials as Topic
• Humans
• Iodine Radioisotopes
• Lymphoma, B-Cell (immunology, radiotherapy)
• Radioimmunotherapy
• Rituximab
• Splenomegaly
• Yttrium Radioisotopes